Screener
Amneal Pharmaceuticals, Inc. AMRX Other therapeutic classes — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Specialty | ||||
| Central nervous system | 95,344 | 83,425 | 178,727 | 151,035 |
| Hormonal / allergy | 42,099 | 35,418 | 78,031 | 69,617 |
| Other therapeutic classes | 11,852 | 8,700 | 25,802 | 15,188 |
| Subtotal therapeutic classes | 149,295 | 127,543 | 282,560 | 235,840 |
| License agreement | — | 500 | — | 500 |
| Total Specialty net revenue | 149,295 | 128,043 | 282,560 | 236,340 |
| AvKARE |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s other therapeutic classes — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported other therapeutic classes — net revenue of $11.85M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s other therapeutic classes — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s other therapeutic classes — net revenue increased by 36.2% year-over-year, from $8.7M to $11.85M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s other therapeutic classes — net revenue?
- Over 2 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s other therapeutic classes — net revenue has grown at a -37.8% compound annual growth rate (CAGR), from $102.65M to $39.66M.
- What does other therapeutic classes — net revenue mean?
- This metric represents the total net revenue generated from pharmaceutical products categorized outside of the company's primary therapeutic focus areas. It captures the financial contribution of niche or legacy product lines that do not fall under the core Generics or Specialty segments. Monitoring this revenue stream helps investors assess the performance of diversified product portfolios and the impact of portfolio rationalization strategies.
Ask your AI about Amneal Pharmaceuticals, Inc.'s other therapeutic classes — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude